{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:32:53Z","timestamp":1790659973450,"version":"4.1.0"},"reference-count":122,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Human Resources Development, Education and Lifelong Learning 2014-2020","award":["MIS 5033021"],"award-info":[{"award-number":["MIS 5033021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Immunotherapy with chimeric antigen receptor T (CAR-T cells) has been recently approved for patients with relapsed\/refractory B-lymphoproliferative neoplasms. Along with great efficacy in patients with poor prognosis, CAR-T cells have been also linked with novel toxicities in a significant portion of patients. Cytokine release syndrome (CRS) and neurotoxicity present with unique clinical phenotypes that have not been previously observed. Nevertheless, they share similar characteristics with endothelial injury syndromes developing post hematopoietic cell transplantation (HCT). Evolution in complement therapeutics has attracted renewed interest in these life-threatening syndromes, primarily concerning transplant-associated thrombotic microangiopathy (TA-TMA). The immune system emerges as a key player not only mediating cytokine responses but potentially contributing to endothelial injury in CAR-T cell toxicity. The interplay between complement, endothelial dysfunction, hypercoagulability, and inflammation seems to be a common denominator in these syndromes. As the indications for CAR-T cells and patient populations expand, there in an unmet clinical need of better understanding of the pathophysiology of CAR-T cell toxicity. Therefore, this review aims to provide state-of-the-art knowledge on cellular therapies in clinical practice (indications and toxicities), endothelial injury syndromes and immunity, as well as potential therapeutic targets.<\/jats:p>","DOI":"10.3390\/ijms21113886","type":"journal-article","created":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T04:09:03Z","timestamp":1591070943000},"page":"3886","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["A New Era in Endothelial Injury Syndromes: Toxicity of CAR-T Cells and the Role of Immunity"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-8208","authenticated-orcid":false,"given":"Eleni","family":"Gavriilaki","sequence":"first","affiliation":[{"name":"Hematology Department\u2014BMT Unit, G Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Sakellari","sequence":"additional","affiliation":[{"name":"Hematology Department\u2014BMT Unit, G Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriilaki","sequence":"additional","affiliation":[{"name":"Laboratory of Clinical Neurophysiology, AHEPA Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilles","family":"Anagnostopoulos","sequence":"additional","affiliation":[{"name":"Hematology Department\u2014BMT Unit, G Papanicolaou Hospital, 57010 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"ref_1","unstructured":"Sakellari, I. (2010). Hematopoietic stem cell transplantation: Historical perspectives. New Insights in Hematopoietic Cell Transplantation, Research Signpost."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5840286","DOI":"10.1155\/2019\/5840286","article-title":"Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents","volume":"2019","author":"Gavriilaki","year":"2019","journal-title":"Stem Cells Int."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/sj.bmt.1705956","article-title":"The EBMT activity survey 2006 on hematopoietic stem cell transplantation: Focus on the use of cord blood products","volume":"41","author":"Gratwohl","year":"2008","journal-title":"Bone Marrow Transpl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2019000151","article-title":"Tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma patients without measurable disease at infusion","volume":"3","author":"Bishop","year":"2019","journal-title":"Blood Adv."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1055\/s-0039-1692721","article-title":"Linking Complement Activation, Coagulation, and Neutrophils in Transplant-Associated Thrombotic Microangiopathy","volume":"119","author":"Gavriilaki","year":"2019","journal-title":"Thromb. Haemost."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/CJI.0000000000000307","article-title":"Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib","volume":"43","author":"Qin","year":"2020","journal-title":"J. Immunother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","article-title":"CAR T cells: Continuation in a revolution of immunotherapy","volume":"21","author":"Singh","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1924379","DOI":"10.1155\/2020\/1924379","article-title":"CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead","volume":"2020","author":"Zhang","year":"2020","journal-title":"J. Immunol. Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Davila, M.L., Kloss, C.C., Gunset, G., and Sadelain, M. (2013). CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061338"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/cgt.2015.5","article-title":"Performance-enhancing drugs: Design and production of redirected chimeric antigen receptor (CAR) T cells","volume":"22","author":"Levine","year":"2015","journal-title":"Cancer Gene Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.bbmt.2019.12.093","article-title":"Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in 3 Ongoing Clinical Studies in Relapsed\/Refractory (R\/R) Large B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Noneligible (TNE) Patients: Transcend NHL 001, Outreach, and PILOT","volume":"26","author":"Bachier","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Schulthess, D., Gassull, D., Makady, A., Ludlow, A., Rothman, B., Have, P.T., Wu, Y., Ekstrom, L., Minnema, M., and Jagasia, M. (2019). Are CAR-T therapies living up to their hype? A study using real-world data in two cohorts to determine how well they are actually working in practice compared with bone marrow transplants. BMJ Evid. Based Med.","DOI":"10.1136\/bmjebm-2019-111226"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1200\/JCO.2018.36.15_suppl.7505","article-title":"Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R\/R aggressive NHL","volume":"36","author":"Abramson","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Hunter, B.D., and Jacobson, C.A. (2019). CAR T-cell associated neurotoxicity: Mechanisms, clinicopathologic correlates, and future directions. J. Natl. Cancer Inst.","DOI":"10.1093\/jnci\/djz017"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11940-019-0580-3","article-title":"Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment","volume":"21","author":"Rice","year":"2019","journal-title":"Curr. Treat. Options Neurol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bmt.2011.65","article-title":"The role of the endothelium in the short-term complications of hematopoietic SCT","volume":"46","author":"Carreras","year":"2011","journal-title":"Bone Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2215\/CJN.02070508","article-title":"Renal thrombotic microangiopathy after hematopoietic cell transplant: Role of GVHD in pathogenesis","volume":"4","author":"Changsirikulchai","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/ajh.20648","article-title":"Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation","volume":"81","author":"Nakamae","year":"2006","journal-title":"Am. J. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/bmt.2009.230","article-title":"Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning","volume":"45","author":"Willems","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/01.tp.0000230373.82376.46","article-title":"Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation","volume":"82","author":"Uderzo","year":"2006","journal-title":"Transplantation"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bbmt.2005.06.001","article-title":"Blood and marrow transplant clinical trials network toxicity committee consensus summary: Thrombotic microangiopathy after hematopoietic stem cell transplantation","volume":"11","author":"Ho","year":"2005","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1182\/blood-2014-03-564997","article-title":"Diagnostic and risk criteria for HSCT-associated thrombotic microangiopathy: A study in children and young adults","volume":"124","author":"Jodele","year":"2014","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/j.bbmt.2018.12.840","article-title":"Thrombotic Microangiopathy Following Pediatric Autologous Hematopoietic Cell Transplantation: A Report of Significant End-Organ Dysfunction in Eculizumab-Treated Survivors","volume":"25","author":"Schoettler","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/bmt.2013.55","article-title":"GVHD-associated chronic kidney disease after allogeneic haematopoietic cell transplantation","volume":"48","author":"Sakellari","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1002\/acn3.50909","article-title":"Neurologic complications after allogeneic transplantation: A meta-analysis","volume":"6","author":"Gavriilaki","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s00415-019-09372-3","article-title":"Neurological adverse events post allogeneic hematopoietic cell transplantation: Major determinants of morbidity and mortality","volume":"266","author":"Sakellari","year":"2019","journal-title":"J. Neurol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.blre.2019.03.003","article-title":"Hypertension in hematologic malignancies and hematopoietic cell transplantation: An emerging issue with the introduction of novel treatments","volume":"35","author":"Gavriilaki","year":"2019","journal-title":"Blood Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.bbmt.2014.02.012","article-title":"Late cardiovascular complications after hematopoietic cell transplantation","volume":"20","author":"Chow","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2007-03-082933","article-title":"Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: Report from the Bone Marrow Transplant Survivor Study","volume":"110","author":"Bhatia","year":"2007","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/jca.21660","article-title":"Favorable impact of extracorporeal photopheresis in acute and chronic graft versus host disease: Prospective single-center study","volume":"33","author":"Sakellari","year":"2018","journal-title":"J. Clin. Apher."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Sakellari, I., Gavriilaki, E., Kaliou, M., Mallouri, D., Batsis, I., Yannaki, E., Smias, C., Sotiropoulos, D., Tsorlini, E., and Anagnostopoulos, A. (2017). Candida is an emerging pathogen beyond the neutropenic period of allogeneic hematopoietic cell transplantation. Clin. Transplant., 31.","DOI":"10.1111\/ctr.12921"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/jmv.21696","article-title":"Hematopoietic cell transplantation and emerging viral infections","volume":"82","author":"Chatzidimitriou","year":"2010","journal-title":"J. Med Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/ajh\/hpz116","article-title":"Endothelial Microvesicles Circulating in Peripheral and Coronary Circulation Are Associated With Central Blood Pressure in Coronary Artery Disease","volume":"32","author":"Gkaliagkousi","year":"2019","journal-title":"Am. J. Hypertens."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.bbmt.2008.04.005","article-title":"Evaluation of angiopoietins and cell-derived microparticles after stem cell transplantation","volume":"14","author":"Nomura","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/01.tp.0000209218.24916.ba","article-title":"Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipients","volume":"81","author":"Pihusch","year":"2006","journal-title":"Transplantation"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"23360","DOI":"10.18632\/oncotarget.15579","article-title":"Endothelial microparticles delivering microRNA-155 into T lymphocytes are involved in the initiation of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/bmt.2015.52","article-title":"Sinusoidal obstruction syndrome\/veno-occlusive disease: Current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)","volume":"50","author":"Mohty","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.clml.2017.06.008","article-title":"The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies","volume":"17","author":"Sakellari","year":"2017","journal-title":"Clin. LymphomaMyeloma Leuk."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s00277-018-3383-9","article-title":"Long-term outcomes of total body irradiation plus cyclophosphamide versus busulfan plus cyclophosphamide as conditioning regimen for acute lymphoblastic leukemia: A comparative study","volume":"97","author":"Sakellari","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lambert, J., Pautas, C., Terre, C., Raffoux, E., Turlure, P., Caillot, D., Legrand, O., Thomas, X., Gardin, C., and Gogat-Marchant, K. (2018). Gemtuzumab ozogamicin for de novo acute myeloid leukemia: Final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial. Haematologica.","DOI":"10.3324\/haematol.2018.188888"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/cncr.31249","article-title":"Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE","volume":"124","author":"Jabbour","year":"2018","journal-title":"Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.thromres.2005.10.010","article-title":"Veno-occlusive disease prophylaxis with fresh frozen plasma and heparin in bone marrow transplantation","volume":"118","author":"Batsis","year":"2006","journal-title":"Thromb. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3389\/fimmu.2019.00337","article-title":"Complement in Thrombotic Microangiopathies: Unraveling Ariadne\u2019s Thread Into the Labyrinth of Complement Therapeutics","volume":"10","author":"Gavriilaki","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Gavriilaki, E., and Brodsky, R.A. (2020). Complementopathies and precision medicine. J. Clin. Investig.","DOI":"10.1172\/JCI136094"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00281-011-0280-x","article-title":"Interactions between coagulation and complement--their role in inflammation","volume":"34","author":"Oikonomopoulou","year":"2012","journal-title":"Semin. Immunopathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/MBC.0000000000000720","article-title":"Complement-coagulation connections","volume":"29","author":"Conway","year":"2018","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/0161-5890(79)90089-0","article-title":"Isotypes of IgG: Comparison of the primary structures of three pairs of isotypes which differ in their ability to activate complement","volume":"16","author":"Brunhouse","year":"1979","journal-title":"Mol. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.4049\/jimmunol.135.1.445","article-title":"The membrane attack complex of complement: Relation of C7 to the metastable membrane binding site of the intermediate complex C5b-7","volume":"135","author":"Preissner","year":"1985","journal-title":"J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/j.1582-4934.2008.00350.x","article-title":"The alternative complement pathway revisited","volume":"12","author":"Harboe","year":"2008","journal-title":"J. Cell. Mol. Med."},{"key":"ref_55","first-page":"412","article-title":"Local release of properdin in the cellular microenvironment: Role in pattern recognition and amplification of the alternative pathway of complement","volume":"3","author":"Cortes","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1749-6632.1983.tb18116.x","article-title":"Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3","volume":"421","author":"Pangburn","year":"1983","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1084\/jem.143.2.241","article-title":"Multiple sedimenting species of properdin in human serum and interaction of purified properdin with the third component of complement","volume":"143","author":"Chapitis","year":"1976","journal-title":"J. Exp. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Barnum, S., and Schein, T. (2018). Chapter 27\u2014Properdin A2. The Complement FactsBook, Academic Press. [2nd ed.].","DOI":"10.1016\/B978-0-12-810420-0.00002-X"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1128\/IAI.68.2.688-693.2000","article-title":"Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition","volume":"68","author":"Neth","year":"2000","journal-title":"Infect. Immun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1099\/0022-1317-81-4-949","article-title":"Interaction of mannose-binding lectin with primary isolates of human immunodeficiency virus type 1","volume":"81","author":"Saifuddin","year":"2000","journal-title":"J. Gen. Virol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"10498","DOI":"10.1073\/pnas.1202588109","article-title":"Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2","volume":"109","author":"Heja","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","article-title":"The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy","volume":"127","author":"Jodele","year":"2016","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/bloodadvances.2017008250","article-title":"In vitro evidence of complement activation in transplantation-associated thrombotic microangiopathy","volume":"1","author":"Rotz","year":"2017","journal-title":"Blood Adv."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Gavriilaki, E., Touloumenidou, T., Sakellari, I., Batsis, I., Mallouri, D., Psomopoulos, F., Tsagiopoulou, M., Koutra, M., Yannaki, E., and Papalexandri, A. (2020). Pretransplant Genetic Susceptibility: Clinical Relevance in Transplant-Associated Thrombotic Microangiopathy. Thromb. Haemost.","DOI":"10.1055\/s-0040-1702225"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/bloodadvances.2020001515","article-title":"Interferon-complement loop in transplant-associated thrombotic microangiopathy","volume":"4","author":"Jodele","year":"2020","journal-title":"Blood Adv."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bbmt.2016.12.459","article-title":"Thrombotic Microangiopathy Can Occur Before Transplant in Children with HLH","volume":"23","author":"Gloude","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e003573","DOI":"10.1136\/bmjopen-2013-003573","article-title":"A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)","volume":"3","author":"Rathbone","year":"2013","journal-title":"BMJ Open"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.bbmt.2016.03.032","article-title":"Terminal Complement Blockade after Hematopoietic Stem Cell Transplantation Is Safe without Meningococcal Vaccination","volume":"22","author":"Jodele","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/bmt.2016.87","article-title":"Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy","volume":"51","author":"Vasu","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000000601","article-title":"Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC","volume":"99","author":"Galambrun","year":"2015","journal-title":"Transplantation"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1016\/j.bbmt.2017.08.019","article-title":"Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy","volume":"23","author":"Bohl","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Jodele, S., Dandoy, C.E., Lane, A., Laskin, B.L., Teusink-Cross, A., Myers, K.C., Wallace, G.H., Nelson, A., Bleesing, J., and Chima, R.S. (2020). Complement blockade for TA-TMA: Lessons learned from large pediatric cohort treated with eculizumab. Blood.","DOI":"10.1182\/blood.2019004218"},{"key":"ref_74","unstructured":"Rambaldi, A., Khaled, S., Smith, M., Zecca, M., Kwong, Y.L., Claes, K., Leung, N., and Whitaker, S. (2018). Improved Survival Following OMS721 Treatment of Hematopoieic Stem Cell Transplant-associated Thrombotic Microangiopathy (HCT-TMA), EHA 2018."},{"key":"ref_75","first-page":"698","article-title":"Enhanced anaphylatoxin and terminal C5b-9 complement complex formation in patients with the syndrome of hemolysis, elevated liver enzymes, and low platelet count","volume":"76","author":"Haeger","year":"1990","journal-title":"Obstet. Gynecol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1161\/HYPERTENSIONAHA.113.01420","article-title":"Urinary excretion of C5b-9 in severe preeclampsia: Tipping the balance of complement activation in pregnancy","volume":"62","author":"Burwick","year":"2013","journal-title":"Hypertension"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.exphem.2016.01.005","article-title":"Direct evidence of complement activation in HELLP syndrome: A link to atypical hemolytic uremic syndrome","volume":"44","author":"Vaught","year":"2016","journal-title":"Exp. Hematol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Salmon, J.E., Heuser, C., Triebwasser, M., Liszewski, M.K., Kavanagh, D., Roumenina, L., Branch, D.W., Goodship, T., Fremeaux-Bacchi, V., and Atkinson, J.P. (2011). Mutations in complement regulatory proteins predispose to preeclampsia: A genetic analysis of the PROMISSE cohort. PLoS Med., 8.","DOI":"10.1371\/journal.pmed.1001013"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Vaught, A.J., Braunstein, E.M., Jasem, J., Yuan, X., Makhlin, I., Eloundou, S., Baines, A.C., Merrill, S.A., Chaturvedi, S., and Blakemore, K. (2018). Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight, 3.","DOI":"10.1172\/jci.insight.99128"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.4049\/jimmunol.1701695","article-title":"Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy","volume":"200","author":"Osborne","year":"2018","journal-title":"J. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/cge.13392","article-title":"Genotype-phenotype correlations of low-frequency variants in the complement system in renal disease and age-related macular degeneration","volume":"94","author":"Geerlings","year":"2018","journal-title":"Clin. Genet."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00277-017-3092-9","article-title":"Plasma levels of complement activation fragments C3b and sC5b-9 significantly increased in patients with thrombotic microangiopathy after allogeneic stem cell transplantation","volume":"96","author":"Qi","year":"2017","journal-title":"Ann. Hematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/sj.bmt.1701211","article-title":"Hepatic veno-occlusive disease with severe capillary leakage after peripheral stem cell transplantation: Treatment with recombinant plasminogen activator and C1-esterase inhibitor concentrate","volume":"21","author":"Heying","year":"1998","journal-title":"Bone Marrow Transplant."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.bbmt.2010.09.002","article-title":"Is complement alternative pathway disregulation involved in veno-occlusive disease of the liver?","volume":"16","author":"Bucalossi","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1182\/blood-2015-02-629683","article-title":"Modified Ham test for atypical hemolytic uremic syndrome","volume":"125","author":"Gavriilaki","year":"2015","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00701-011-1122-2","article-title":"Dexamethasone inhibits ICAM-1 and MMP-9 expression and reduces brain edema in intracerebral hemorrhagic rats","volume":"153","author":"Yang","year":"2011","journal-title":"Acta Neurochir."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11906-015-0596-3","article-title":"Clinical Significance of Endothelial Dysfunction in Essential Hypertension","volume":"17","author":"Gkaliagkousi","year":"2015","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s11684-019-0714-8","article-title":"Management of cytokine release syndrome related to CAR-T cell therapy","volume":"13","author":"Chen","year":"2019","journal-title":"Front. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1038\/s41467-019-10565-7","article-title":"Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters","volume":"10","author":"Lee","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_97","first-page":"1981","article-title":"CAR-T cell therapy causes inflammation by IL-1 which activates inflammatory cytokine mast cells: Anti-inflammatory role of IL-37","volume":"33","author":"Caraffa","year":"2019","journal-title":"J. Biol. Regul. Homeost. Agents"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","article-title":"Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: An open-label, phase 3, randomised controlled trial","volume":"379","author":"Corbacioglu","year":"2012","journal-title":"Lancet"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.bbmt.2018.02.015","article-title":"Defibrotide for Sinusoidal Obstruction Syndrome\/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study","volume":"24","author":"Picod","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: The 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: The 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood-2019-128746","article-title":"One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment","volume":"134","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1182\/blood-2019-128929","article-title":"Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: An infectious diseases perspective (Soluble immune effector molecules [II]: Agents targeting interleukins, immunoglobulins and complement factors)","volume":"24","author":"Winthrop","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrd4657","article-title":"Complement, a target for therapy in inflammatory and degenerative diseases","volume":"14","author":"Morgan","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrneph.2017.156","article-title":"The renaissance of complement therapeutics","volume":"14","author":"Ricklin","year":"2018","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1053\/j.seminhematol.2018.02.002","article-title":"Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria","volume":"55","author":"Mastellos","year":"2018","journal-title":"Semin. Hematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood-2019-126911","article-title":"Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes","volume":"134","author":"Sostelly","year":"2019","journal-title":"Blood"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood-2019-124837","article-title":"Mechanistic Evaluation of Efficacy Using Biomarkers of the Oral, Small Molecule Factor D Inhibitor, Danicopan (ACH-4471), in Untreated Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)","volume":"134","author":"Risitano","year":"2019","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1182\/blood-2019-124748","article-title":"A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy","volume":"134","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1182\/blood.V128.22.2431.2431","article-title":"Evaluation of Bacteria-Mediated Potential \u201cBystander\u201d Hemolysis of PNH RED CELLS In Vitro: NO Evidence of Significant Complement Classical or Lectin Pathway-Mediated Hemolysis Induced by Microorganisms","volume":"128","author":"Yuan","year":"2016","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood-2017-05-781450","article-title":"Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults","volume":"130","author":"Konar","year":"2017","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1182\/blood-2018-99-110827","article-title":"Inhibition of C3 with APL-2 Results in Normalisation of Markers of Intravascular and Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)","volume":"132","author":"Wong","year":"2018","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Gralinski, L.E., Sheahan, T.P., Morrison, T.E., Menachery, V.D., Jensen, K., Leist, S.R., Whitmore, A., Heise, M.T., and Baric, R.S. (2018). Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio, 9.","DOI":"10.1128\/mBio.01753-18"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1097\/ALN.0000000000003149","article-title":"Neutralizing Complement C5a Protects Mice with Pneumococcal Pulmonary Sepsis","volume":"132","author":"Kellermann","year":"2020","journal-title":"Anesthesiology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41426-018-0063-8","article-title":"Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV","volume":"7","author":"Jiang","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Risitano, A.M., Mastellos, D.C., Huber-Lang, M., Yancopoulou, D., Garlanda, C., Ciceri, F., and Lambris, J.D. (2020). Complement as a target in COVID-19?. Nat. Rev. Immunol., -7.","DOI":"10.1038\/s41577-020-0320-7"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4239\/wjd.v11.i1.1","article-title":"Complement activation in obesity, insulin resistance, and type 2 diabetes mellitus","volume":"11","author":"Shim","year":"2020","journal-title":"World J. Diabetes"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Mastaglio, S., Ruggeri, A., Risitano, A.M., Angelillo, P., Yancopoulou, D., Mastellos, D.C., Huber-Lang, M., Piemontese, S., Assanelli, A., and Garlanda, C. (2020). The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin. Immunol, 108450.","DOI":"10.1016\/j.clim.2020.108450"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Gavriilaki, E., and Brodsky, R.A. (2020). Severe COVID-19 infection and thrombotic microangiopathy: Success doesn\u2019t come easily. Br. J. Haematol.","DOI":"10.1111\/bjh.16783"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/11\/3886\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:33:46Z","timestamp":1760175226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/11\/3886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":122,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["ijms21113886"],"URL":"https:\/\/doi.org\/10.3390\/ijms21113886","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]}}}